A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection
Rui Hua, Junqi Niu(Jilin University), Bin Xu(Memorial Sloan Kettering Cancer Center), Yongning Xin(Qingdao University), Yujuan Guan(Guangzhou Eighth People's Hospital), Chenxin Meng(The Sixth People's Hospital of Shenyang), Jiefei Wang(CAE (Canada)), Yanhua Ding, H. Ma(Tianjin People's Hospital), Cheng Li(Guangzhou Medical University), Jiayu Chen(East China University of Science and Technology), Zhiqiang Wang(Harbin Normal University), Xian Zhang(Central South University), Guangming Li(The Sixth People's Hospital of Zhengzhou), Yan Huang(Fudan University), Yuexin Zhang, Qingfang Xiong(Nanjing Second Hospital), Fei Kong(Shanghai Jiao Tong University), Youwen Tan(Jiangsu University), Xiaofeng Wen(Liuzhou General Hospital), Xiaorong Mao(First Hospital of Lanzhou University), Yongfang Jiang(Central South University), Hainv Gao
Cited by 1
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome
|The Lancet|2013|839
Psychological impacts and coping strategies of front-line medical staff during COVID-19 outbreak in Hunan, China
|Medical Science Monitor|2020|784
Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection
|New England Journal of Medicine|2013|655
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644